Melcher C, Scholz C, Jäger B, Hagenbeck C, Rack B, Janni W
Women's Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf.
Department and Outpatient Clinic for Gynaecology and Obstetrics - Innenstadt, Hospital of the Ludwig Maximilian , University of Munich, Munich.
Geburtshilfe Frauenheilkd. 2012 Mar;72(3):215-224. doi: 10.1055/s-0031-1298320.
Advances in research have a highly influential role to play in the strategy of early detection, treatment and aftercare of breast cancer and therefore everyday clinical practice. Newly-defined prognosis factors and a new form of molecular subtype classification, for example, are intended to help identify patients who will actually benefit from chemotherapy. In the field of neoadjuvant chemotherapy, the inclusion of the angiogenesis inhibitor Bevacizumab and dual antiHER2 therapy is being discussed. What's more, where defined criteria are met, even with positive sentinel lymph nodes, axillary dissection is not performed; besides bisphosphonates RANKL antibody Denosumab is now an option in the treatment of bone metastases.
研究进展在乳腺癌的早期检测、治疗及后续护理策略中，进而在日常临床实践中发挥着极具影响力的作用。例如，新定义的预后因素和新的分子亚型分类形式旨在帮助识别真正能从化疗中获益的患者。在新辅助化疗领域，正在讨论将血管生成抑制剂贝伐单抗和双重抗HER2治疗纳入其中。此外，在满足特定标准的情况下，即使前哨淋巴结呈阳性，也不进行腋窝淋巴结清扫；除双膦酸盐外，RANKL抗体地诺单抗现在也是治疗骨转移的一种选择。
